Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NHWD 870

Next Previous
Drug Profile

NHWD 870

Alternative Names: NHWD-870

Latest Information Update: 05 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ningbo Wenda Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors; Mitogen-activated protein kinase inhibitors; Platelet-derived growth factor beta receptor modulators; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-myc inhibitors; Proto-oncogene protein inhibitors; STAT1 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Squamous cell cancer
  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 05 Aug 2024 Phase-I clinical trials in Non-Hodgkin's lymphoma (PO), prior to August 2024 (Wenda pharma pipeline, August 2024)
  • 05 Aug 2024 Ningbo Wenda Pharma announces intention to submit NDA to regulatory body for Squamous cell cancer in 2025 (Ningbo Wenda Pharma pipeline, August 2024)
  • 25 Apr 2024 Phase-II clinical trials in Squamous cell cancer (Late-stage disease, In adolescents, In adults, In the elderly) in China (PO) (NCT06527300)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top